Roberto C. Fernandez-Guerri

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 35 publications

actHIVa Cataluña: Consensus to improve comprehensive care and long-term quality of life for vulnerable people living with HIV in Catalonia.

actHIVa Cataluña: Consensus to improve comprehensive care and long-term quality of life for vulnerable people living with HIV in Catalonia.

Journal: Enfermedades infecciosas y microbiologia clinica (English ed.)

Published: December 15, 2025

Proof-of-Concept Phase 2a Trial of VH4524184 (VH-184), an Emerging Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance Profile.

Proof-of-Concept Phase 2a Trial of VH4524184 (VH-184), an Emerging Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance Profile.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: December 02, 2025

Challenges in the Vaccination of HIV-Infected Individuals.

Challenges in the Vaccination of HIV-Infected Individuals.

Journal: Vaccines

Published: November 25, 2025

Global and Sex-Stratified Genome-Wide Association Study of Long COVID Based on Patient-Driven Symptom Recall.

Global and Sex-Stratified Genome-Wide Association Study of Long COVID Based on Patient-Driven Symptom Recall.

Journal: International journal of molecular sciences

Published: August 04, 2025

Sex Differences in Long COVID Prevalence Over One year After the Acute Phase, and Related Risk Factors. The GINA-COVID Cohort Study.

Sex Differences in Long COVID Prevalence Over One year After the Acute Phase, and Related Risk Factors. The GINA-COVID Cohort Study.

Journal: International journal of women's health

Published: May 05, 2025

Short Assessment for People with Human Immunodeficiency Virus (HIV) Aged 50 Years or Older: Essential Tests from Comprehensive Geriatric Assessment.

Short Assessment for People with Human Immunodeficiency Virus (HIV) Aged 50 Years or Older: Essential Tests from Comprehensive Geriatric Assessment.

Journal: Viruses

Published: April 29, 2025

Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial.

Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial.

Journal: The lancet. HIV

Published: February 18, 2025

Baseline medication profile and risk of CYP3A4 mediated drug-drug interactions among COVID-19 hospitalized patients in Spain.

Baseline medication profile and risk of CYP3A4 mediated drug-drug interactions among COVID-19 hospitalized patients in Spain.

Journal: BMC infectious diseases

Published: January 29, 2025

Serum-derived bovine immunoglobulin treatment in COVID-19 is associated with faster resolution of symptoms: A randomized pilot clinical trial.

Serum-derived bovine immunoglobulin treatment in COVID-19 is associated with faster resolution of symptoms: A randomized pilot clinical trial.

Journal: Journal of medical virology

Published: May 23, 2024

Anti-PD-L1 Immunotherapy of Chronic Virus Infection Improves Virus Control without Augmenting Tissue Damage by Fibrosis.

Anti-PD-L1 Immunotherapy of Chronic Virus Infection Improves Virus Control without Augmenting Tissue Damage by Fibrosis.

Journal: Viruses

Published: January 18, 2024

Genetic characteristics involved in COVID-19 severity. The CARGENCORS case-control study and meta-analysis.

Genetic characteristics involved in COVID-19 severity. The CARGENCORS case-control study and meta-analysis.

Journal: Journal of medical virology

Published: September 13, 2023

Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study.

Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study.

Journal: HIV research & clinical practice

Published: July 26, 2023

Showing 1-12 of 35

Last Updated: 09/26/2026